Wells Fargo says that Avadel Pharmaceuticals (AVDL) settlement adds $5 to Jazz Pharmaceuticals’ (JAZZ) DCF, but the firm notes that the investment thesis for the latter centers around the GEA readout later this year. The settlement with Avadel may reduce uncertainty for Jazz Pharmaceuticals, Wells adds. The firm has an Overweight rating on Jazz with a price target of $170 on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- Avadel announces global settlement of all litigation with Jazz Pharmaceuticals
- Jazz Pharmaceuticals price target raised to $180 from $167 at Morgan Stanley
- Positive Outlook for Jazz Pharmaceuticals: Oncology Launches and Strategic Moves Drive Buy Recommendation
- Jazz Pharmaceuticals Completes Study on Promising HER2 Cancer Treatment
- Jazz Pharmaceuticals price target raised to $230 from $225 at BofA